BrightGene Bio-Medical Technology Co. Ltd.SSE: 688166

2025 Annual Report

Mar 20, 2026 · Issued by BrightGene Bio-Medical Technology Co. Ltd. via Shanghai Stock Exchange

Filed with SSE · Mar 20, 2026

On 6ix: 6ix.com/news/2025-annual-report-149

2025 Annual Report

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

6ix hasn’t read this filing yet.

BrightGene Bio-Medical Technology Co. Ltd. on 6ix

Earlier from BrightGene Bio-Medical Technology

Announcement on Outward Investment and Related Party TransactionsMar 11
Announcement on Preliminary Earnings Estimate for 2025Feb 28
Announcement on Voluntary Disclosure of the Proposed Selection of Partial Products in the National Continuation Drug ProcurementFeb 12
Earnings Preannouncement for 2025Jan 31
Announcement on Not Redeeming ""BrightGene Convertible Bonds"" in AdvanceJan 6

Later from BrightGene Bio-Medical Technology

Announcement on Convening the 2025 Annual Performance BriefingMar 25
BrightGene Announces Positive Topline Phase 1 Results of Oral BGM0504 in Obesity in China and the United StatesMar 25
Announcement on Resignation of the Directors and Senior Management MembersMar 31
Announcement on Adding Provisional Proposal at 2025 Annual General MeetingApr 2
Announcement on Resolutions of the 2025 Annual General MeetingApr 11

All BrightGene Bio-Medical Technology news releases

Follow BrightGene Bio-Medical Technology into a list and get an email when it puts out news.

Follow BrightGene Bio-Medical Technology